Appointment of Internal Auditor: The Board of Directors based on the recommendation of the Audit Committee, has approved the appointment of M/s. S K Doshi & Associates for the financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Coral Laboratories' board approved audited standalone results for Q4 and FY ended March 31, 2025, with the statutory auditor (M.A. Parekh & Associates) issuing an unmodified opinion. Full-year revenue from operations grew strongly to ₹11,500.53 lakh versus ₹8,366.04 lakh last year, and net profit jumped to ₹2,415.56 lakh from ₹1,578.90 lakh, taking EPS to ₹67.61 (vs ₹44.19). The board recommended a 15% final dividend (₹1.50 per share on ₹10 face value) for FY25, subject to shareholder approval. The company also appointed SARK & Associates LLP as secretarial auditor for five years (FY26–FY30), S K Doshi & Associates as internal auditor for FY26, and Aatish Dhatrak & Associates as cost auditor for FY26.
Strong full-year growth (revenue up ~37% and profit up ~53%) with an unmodified audit opinion and a 15% dividend are positive for shareholders. However, Q4 FY25 profit of ₹282.71 lakh was roughly half of ₹578.70 lakh in Q4 FY24, which may temper near-term sentiment despite the strong annual numbers.